Quick Answer
Janux Therapeutics, Inc. reported Total Assets of $1.00 billion for the year ending 2025.
- Janux Therapeutics, Inc. showed a decrease of -5.6% in Total Assets from 2024 to 2025.
- This data is from Janux Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $396.82 million | Q3 2021: $391.08 million | Q1 2022: $368.60 million | Q2 2022: $385.37 million | Q3 2022: $375.76 million | Q1 2023: $352.96 million | Q2 2023: $341.50 million | Q3 2023: $386.85 million | Q1 2024: $688.98 million | Q2 2024: $691.41 million | Q3 2024: $695.02 million | Q1 2025: $1.05 billion | Q2 2025: $1.03 billion | Q3 2025: $1.02 billion.
- Over the full 6 years of available data (2020 to 2025), Janux Therapeutics, Inc.'s Total Assets has grown by 6,076.0%.
- Historical annual values: Fiscal year 2025: $1.00 billion | Fiscal year 2024: $1.06 billion | Fiscal year 2023: $380.41 million | Fiscal year 2022: $364.01 million | Fiscal year 2021: $379.82 million | Fiscal year 2020: $16.22 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: